Novel device for high-dose chemotherapy delivery during transarterial chemoembolization

Tech ID: 23088 / UC Case 2010-112-0

Background

Systemic chemotherapy has been associated with damage to healthy tissue and in some cases induction of secondary malignancies. Transarterial chemo-embolization (TACE) is a commonly used procedure in hepatic malignancies designed to reduce the systemic dose. TACE therapy involves administration of chemotherapy directly to the liver via a catheter which is inserted through the femoral artery to the hepatic artery that directly feeds the hepatic tumor. The blood supply to the tumor is then embolized following chemotherapy to further increase the dose to the tumor tissue. Nonetheless, even with TACE up to 50% of administered doxorubicin (Dox) passes directly through hepatic tumors into the systemic circulation. To further increase tumor dose while reducing systemic exposure, UCSF scientists have developed a novel catheter incorporating a chemotherapy filter that is positioned transiently during TACE so as to bind Dox that has passed through the tumor before it enters the systemic circulation.

Technology Description

UCSF scientists have developed a specialized catheter device with filter that can be used in TACE procedures to bind Dox that enters the venous system and might then cause systemic damage. The device is guided to the desired vein via an internal jugular approach. Filters of adsorbent materials have been tested in an in-vitro model to bind and adsorb more than half of the Dox that is administered through the system. Prototype devices have been constructed and the feasibility of a novel intravenous chemotherapy filter device has been successfully demonstrated in-vitro with significant Dox binding in a physiologic TACE flow model. Binding performance has been characterized for various filter materials. Based on these results, physical-chemical properties of the materials are being optimized to develop even more efficient filters prior to in vivo device validation.

Applications

  • Temporary chemotherapy filter to be used in conjunction with TACE (or intra-arterial chemotherapy) placed in the draining vein of the tumor (i.e. hepatic vein, renal vein, or inferior vena cava).

Advantages

  • Drug binding: 50% of injected Dox dose (avg 25 mg) in the average time of TACE drug injection (10 mins). Device can be deployed up to ~60 mins.
  • Allows further increase of chemotherapy dose in a regular TACE procedure.
  • Safety: Biocompatible and drug specific (not thrombogenic, does not cause clinically significant nonspecific binding to blood cells, serum proteins, or electrolytes).
  • Re-adsorb the residual Dox molecules that are leaving the tumor tissue prior to entering the systemic circulation.
  • Large market: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death in the world.    

Patent Status

Country Type Number Dated Case
Hong Kong Issued Patent HK1209018 09/20/2019 2010-112
Japan Issued Patent 6420255 10/19/2018 2010-112
Australia Issued Patent 2013361551 07/05/2018 2010-112
China Issued Patent ZL 201380061710.9 06/15/2018 2010-112
Germany Issued Patent 2934376 06/06/2018 2010-112
France Issued Patent 2934376 06/06/2018 2010-112
United Kingdom Issued Patent 2934376 06/06/2018 2010-112
Brazil Published Application 2427 07/11/2017 2010-112
United States Of America Published Application 20150305850 10/29/2015 2010-112
Canada Published Application 2010-112
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As